Effects of mesenchymal stem cells conditioned medium on behavioral aspects of inflammatory arthritic pain induced by CFA adjuvant by Nazemian, Vida et al.
  Journal of Cellular & Molecular Anesthesia (JCMA)  
47 
1. Neurophysiology Research Centre, 
Shahid Beheshti University of Medical 
Sciences, Tehran, Iran 
2. Department of Physiology, School 
of Medicine, Shahid Beheshti 




























Corresponding Author:  
Jalal Zaringhalam, MD, PhD; 
Neurophysiology Research Centre, 
Physiology Department, Shahid 
Beheshti University of Medical 
Sciences, Tehran, Iran. Tel/Fax: (+98) 
21-88200077. 
Email: jzaringhalam@yahoo.com 
Received: February 15, 2016 
Accepted: March 9, 2016 
Original Article  
 
 
Effects of Mesenchymal Stem Cells Conditioned Medium on 
Behavioral Aspects of Inflammatory Arthritic Pain Induced by 
Complete Freund’s Adjuvant 
 
 
Vida Nazemian1,2, Behzad Nasseri1,2, Homa Manaheji1,2, Jalal Zaringhalam1,2* 
 
Abstract 
Background: Rheumatoid arthritis is a type of inflammatory pain and is an 
autoimmune and chronic inflammatory disease which can lead to 
hyperalgesia, edema and decreased motor activity in affected area. 
Mesenchymal stem cells conditioned medium (MSC-CM) has anti-
inflammatory mediators which can regulate the immune responses, alleviate 
inflammatory symptoms and has a paracrine effects too. The aim of this study 
was to evaluate the effects of mesenchymal stem cells conditioned medium on 
behavioral aspects of inflammatory arthritic pain which induced by Complete 
Freund’s adjuvant (CFA).  
Materials and Methods: Complete Freund’s adjuvant-induced arthritis 
(AA) was caused by single subcutaneous injection of CFA into the rat’s hind 
paw on day zero. MSC-CM was administered daily and intraperitoneal during 
the 21 days of the study after CFA injection. Hyperalgesia and edema were 
assessed on days 0, 7, 14 and 21 of the study respectively with radian heat and 
plethysmometer instrument.  
Results: The results of this study indicated the significant roles of MSC-
CM in betterment of inflammatory symptoms such as hyperalgesia and 
edema during different stages of inflammation caused by CFA. The 
continuing injection of MSC-CM could reduce the inflammatory symptoms.  
Conclusion: Long term treatment by MSC-CM can alleviate hyperalgesia 
and edema and decrease those to the level of the time before induction of 
inflammation. 
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Introduction 
Inflammatory pain is a type of pathological 
pain caused by peripheral tissue inflammation and 
tissue damage which is characterized by an increased 
sensitivity to stimuli of the affected tissue. 
Rheumatoid arthritis (RA) is a type of inflammatory 
pain (1) and is an autoimmune inflammatory disease 
with unknown etiology which has been lead to pain, 
swelling, hyperalgesia, dryness and inflammation of 
the joints and surrounding tissue, cartilage and bone 
destruction, dysfunction and disability (2). The RA 
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disease process is variable, often is associated with 
periods of relapse and sometimes with a reduction in 
symptoms. Despite the unknown etiology of RA, it 
seems that pro-inflammatory cytokines elevated 
during the disease which can cause inflammatory 
symptoms such as hyperalgesia and edema (3). 
Inflammatory biochemical factors such as the kinins, 
prostaglandins, histamine, and serotonin act 
synergistically to induce hyperalgesia as well as 
increased vascular permeability and also development 
of acute pain and edema (4). Hyperalgesia caused due 
to excessive sensitivity of pain receptors because of 
decrease of activation threshold as a result of release 
of some chemicals like histamine, bradykinin and etc. 
The most important cause of progression of 
hyperalgesia is activation of pain afferents during 
inflammation. It seems that the neural mechanism of 
hyperalgesia is sensitization of the primary afferent 
nociceptive fibers (5). Following inflammation and 
injury, an inflammatory response is generated by T-
lymphocytes and this is further amplified by 
producing pro-inflammatory cytokines like TNF-α 
and IL-1β and maintain the development of pain, 
hyperalgesia and edema (1). A variety of factors like 
Complete Freund's Adjuvant (CFA), Formalin, 
Carrageenan and Capsaicin are used to create an 
inflammatory pain model and there are differences in 
underlying mechanisms and clinical symptoms of 
inflammation induced by these adjuvants. Studies 
have shown that inflammation induced by CFA is 
usually more stable than other inflammatory 
adjuvants. Inflammatory pain model induced by CFA 
is a biphasic model that in the first phase 
(inflammatory phase) is associated with increased 
pain due to the presence of inflammatory cytokines 
such as TNF-α and IL-1β, while in the second phase 
(arthritic phase) hyperalgesia due to the elevation of 
opioid receptors expression dramatically decreased 
(6). Mesenchymal stem cell (MSC) is a population of 
pluripotent adult stem cells which have a high 
capacity for self-renewal and proliferation and 
represent functional characteristics which have open 
the way for cell-based therapy for autoimmune 
disorders (7-9). MSCs are able to secrete a wide range 
of trophic factors which can demonstrate paracrine 
effects on other cell types. Hence, mesenchymal stem 
cell conditioned medium (MSC-CM) have shown 
potential therapeutic applications in regeneration or in 
pain alleviation (8). MSC-CM is a supernatant that is 
achieved from in vitro cultured stem cells conditions 
and can cause effects similar to MSC. In recent years 
their eventuality to take part in the immune response 
modulation is discussed (9). The exact mechanisms of 
immune regulation of MSC-CM are not clear yet, but 
interactions with other immune regulatory cells, 
elevation of anti-inflammatory mediators and 
diminution of pro-inflammatory cytokines may be 
involved in this process (8, 9). This has led to the 
expansion of novel applications of MSC-CM for the 
remedy of inflammatory and degenerative rheumatic 
diseases such as RA, osteoarthritis (OA) and also 
bone and cartilage disorders (10). Then, based on the 
potency of MSC-CM in modulation of immune 
responses and inflammatory symptoms, in this study, 
the effects of mesenchymal stem cells conditioned 
medium on behavioral aspects of inflammatory 




In this study, the adult male Wistar rats (n=96) 
weighing 200–220 gr. were used in all experiments. 
These animals were housed in polypropylene cages 
under standard environmental circumstances (22±2ºC, 
humidity 60–70 %, 12 h light/dark cycle) and allowed 
free access to food and water. All the experiments 
were approved by the international association for the 
study of pain and local ethics committee of the 
utilization of animals in research for the treatment of 
animals and the guidelines of the ethical standards for 
the investigations of experimental pain in animals 
were followed precisely (11). 
In order to determine the effect of MSC-CM on 
inflammatory pain model and the effectiveness of this 
treatment, a series of experiments were performed. 
Rats were randomly divided into different 
experimental groups, as follows: (a) CFA group, (b) 
CFA control group, (c) CFA+CM (d) Sham group. 
According to the study procedure, each group was 
divided into four subgroups based on different time 
points of the study (days 0, 7, 14, and 21) and there 
were 6 rats in each subgroup.  
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Experimental procedure 
Complete Freund’s adjuvant (CFA)-induced 
arthritis was evoked by single subcutaneous injection 
of (100µL) heat-killed Mycobacterium tuberculosis 
suspended in sterile mineral oil (10 mg/mL; CFA; 
Sigma, St Louis, MO, USA) into the rats’ right hind 
paw on day zero (under light anesthesia with 
methoxyflurane). The CFA control group was 
received sterile mineral oil once only (100µL) (S.C.). 
First day after CFA injection, unilateral inflammation 
was established in the injected hind paw of rat (acute 
phase), and the next weeks after inflammatory phase 
were arthritic phase (chronic phase). From the first 
day after CFA injection, experimental groups 
received the MSC-CM on a daily basis and were 
injected intraperitoneal (250µL/rat) (i.p.). The sham 
group received sterile mineral oil with single 
subcutaneous (100µL) injection in the rat’s right hind 
paw and also received MSC-CM on a daily basis 
(250µL/rat) (i.p.). In this study, hyperalgesia and paw 
edema were assessed on day 0 (immediately before 
CFA injection), on days 7 (inflammatory phase), 14 
and 21 (arthritic phase) (12). 
MSC-CM preparation and administration 
Bone marrows were obtained from the bone 
marrow of femurs and tibias of two-month-old male 
Wistar rats (weighing 200-250 g) under sterile 
circumstances. The derived tibia and femur bone 
marrow soaked in cold PBS and eliminated adherent 
soft tissues. Bone marrow (includes hematopoietic 
stem cells and stromal cells) were cultured in minimal 
essential medium alpha (α-MEM, Gibco, Invitrogen, 
Carlsbad, CA, USA) containing 15% fetal bovine 
serum ( FBS, Gibco, Invitrogen, Carlsbad, CA, USA) 
and 1% Penicillin/streptomycin (Gibco, Invitrogen, 
Carlsbad, CA, USA) and incubated at 37°C in the 
presence of 5% carbon dioxide. The cells reach to 
passages three were applied for subsequent studies. 
After 48 hours, the medium of cells were replaced. 
The medium used in this step is free of FBS. In the 
next stage, after 48 hours, the medium in flask (MSCs 
supernatant) were gathered and thereupon filtered by 
the 0.2 micrometers. Cell supernatant was reserved at 
-80°C until the injection (13).  
Assessment of CFA-induced arthritis and paw 
edema 
To confirm the correct injection of CFA, paw 
volume was measured in both injected and 
contralateral paws pre and post-injection during 
different time points of the study. This measurement 
was conducted by displacement of an electrolyte 
solution in a plethysmometer (model 7141; Ugo 
Basile, Comerio-Varese, Italy). Briefly, the rat hind 
paw was submerged up to the tibiotarsal joint into the 
electrolyte-filled Perspex cell of the plethysmometer. 
The volume of the liquid displacement, which is 
associated with the paw volume, was illustrated on a 
digital display. Volume measurements were 
performed twice for each paw and the average was 
calculated. The edema was quantified by measuring 
the differences in the paw volume between the day 0 
and other different time points of the study (14, 15).  
Behavioral test (Thermal hyperalgesia assessment) 
Paw withdrawal latencies (PWL) from noxious 
heat using the plantar test were assessed in both CFA-
injected and control paw on Days 0 (before injection 
of CFA), 7, 14, and 21. PWL in response to radiant 
heat by plantar test apparatus was executed in the 
control and experimental groups (Ugo Basilar, Verse, 
Italy). 10-15 minutes before the test, rats were placed 
in a Plexiglas boxes positioned on a glass surface in 
order to habituate to the test environment. The heat 
source (infrared light) was positioned under the 
plantar surface of the affected hind paw and projected 
focally. The digital timer connected to the heat source 
recorded the PWL to the nearest 0.1 s. automatically. 
Heating was terminated at 20 s cut off to prevent 
tissue damage if an animal failed to withdrawals paw 
from the stimulus prior to the cut off. Each rat 
received three trials per hind paw at an interval of 5–
10 min. PWL, for each paw at an interval of 5 - 10 
min, was done and the results are represented as the 
difference in the PWL score between injected paw 
and control paw and statistical comparisons between 
groups assessed this difference. The value obtained in 
the negative expressed the hyperalgesia in the 
inflamed paw (6, 11). 
H =
(Rt1 + Rt2 + Rt3)
3
−
(Lt1 + Lt2 + Lt3)
3
 
H: The difference between the right and the left 
response time (Hyperalgesia). 
Rt: Right PWL  Lt: left PWL 
Statistical analysis 
Results were represented as mean±standard 
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error of mean (SEM). To compare the results within 
the groups (during different time points), repeated 
measurement ANOVA test (One way ANOVA) and 
post hoc Tukey multiple range tests were used and 
unpaired student t- test was applied to identify 
significant differences of the means on the same days 
between groups. SPSS software version 21 was used 
for data analysis and the charts were analyzed by 
Excel. Statistical significance was accepted at p≤0.05 
level. 
Results 
Paw volume variations during different stages of 
inflammation 
CFA injection in the rats hind paw can induce 
inflammation and increased ipsilateral paw volume 
(in the affected paw), which continued up to 21 days 
after CFA injection. Arthritis due to CFA injection 
was evaluated by measurements of paw volumes pre- 
and post-injection (on days 0, 7, 14 and 21). Paw 
volume significantly increased on days 7, 14, and 21 
after CFA injection compared with day 0 and with 
CFA control group (p≤0.01 for day 7 and p≤0.001 for 
day 14 and 21). Paw volume on days 7, 14 and 21 
compared with day 0 in CFA group showed a 
considerable increase (p≤0.01 for day 7 and p≤0.001 
for day 14 and 21). There were no significant 
differences in reduction in paw volume following 
injection of sterile mineral oil to the rat’s right hind 
paw on different days of the study relative to baseline 
in the CFA control group. Additionally, there were no 
significant differences in paw volume of rats during 
21-days of the study in sham group (Hence, the 
results of the sham groups are not shown graphically). 
Daily administration (i.p.) of MSC-CM in the 
CFA+CM group could reduce paw volume. MSC-CM 
injection in CFA+CM group could significantly 
reduce paw edema throughout this study compared to 
same days in CFA group (p≤0.05 for day 7, p≤0.01 
for day 14 and p≤0.001 for day 21). In comparison 
between the groups CFA+CM and CFA, the results 
illustrated that reduction of paw edema following the 
injection of MSC-CM, at day 21 was higher than day 
14 substantially (p≤0.01). Continuing injection of 
MSC-CM decremented paw volume in CFA+CM 
group, so that at day 21 of the experiment, no 
 
Fig. 1.  Paw volume incremented in CFA group in different time points of the study compared to baseline 
substantially. Long-term injection of MSC-CM downturned paw volume significantly. Results presented as 
Mean±SEM (n=6/group). 
** p≤0.01 and *** p≤0.001 for comparing the paw edema variations between baseline and different days of the 
study in CFA group. † p≤0.05 and †† p≤0.01 for comparing the paw volume variations between day 0 and 
different days of the study in CFA+CM group. Δ p≤0.05 and ΔΔ p≤0.01 for illustrating the variations in paw 
volume at day 14 and day 21 compared to day7 in the CFA+CM group. 
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significant distinction in paw volume in CFA+CM 
group compared with CFA control group was 
perceived. 
Variations in thermal hyperalgesia during 
different stages of inflammation 
Intraplantar injection of CFA into the right 
hind paws of rats caused inflammation and 
hyperalgesia in the affected paw, which continued up 
to 21 days after CFA injection. Arthritis due to CFA 
injection was evaluated by measurements of 
hyperalgesia pre- and post-injection (on days 0, 7, 14 
and 21). Hyperalgesia significantly increased on the 
7th day in the CFA group compared with day 0 
(p≤0.001), but the persistence of inflammation 
significantly decreased hyperalgesia on later two days 
of the study (days 14 and 21) compared to baseline. 
Howbeit, there was still a significant increase 
compared to day 0 (p≤0.01). There were no 
significant differences in reduction of thermal 
hyperalgesia following injection of sterile mineral oil 
to the rat’s right hind paw on different days of the 
study relative to baseline in the CFA control group. 
Considerable difference in the PWL between CFA 
and CFA control groups on different time points of 
the study were perceived (p≤0.001). Additionally, 
there were no significant differences in PWL of rats 
during 21-days of the study in sham group (Hence, 
the results of the sham groups are not shown 
graphically). 
Daily administration (i.p.) of MSC-CM in the 
CFA+CM group declined hyperalgesia, as the 
continuity of this injection for 21 days also 
decremented hyperalgesia even more than the 
baseline (p≤0.05). MSC-CM injection in CFA+CM 
group significantly declined thermal hyperalgesia 
throughout this study compared to same days in CFA 
group (p≤0.05 for day 7 and p≤0.001 for days 14 and 
21) and the continued injection for 21 days reduced 
thermal hyperalgesia even more than CFA control 
group. In comparison between the CFA and 
CFA+CM groups, the results illustrated that the rate 
of reduction of thermal hyperalgesia following the 
injection of MSC-CM, at day 21th after CFA injection 
between these two groups was higher than days 7 and 
14 substantially (p≤0.001). Continuing injection of 
MSC-CM decremented PWL in CFA+CM group, so 
that at day 21 of the experiment, no significant 
difference in PWL in CFA+CM group compared with 
 
Fig. 2.  CFA injection increased paw volume significantly, while MSC-CM administration caused a notable 
diminution in paw volume compared with CFA group. Results stated as Mean±SEM (n=6/group). 
 * p≤0.05, ** p≤0.01 and *** p≤0.001 for comparing the paw volume changess between CFA and CFA+CM 
groups in identical days. Δ p≤0.05 and ΔΔ p≤0.01 for comparing the paw volume variations between 
CFA+CM and CFA control groups in identical days. ϴϴ p≤0.01 for comparing the differences in paw volume 
alterations in CFA and CFA+CM groups at day 14 compared to day 21. 
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CFA control group was observed. 
Discussion 
The main objective of the present study was to 
evaluate the effects of mesenchymal stem cells 
conditioned medium on behavioral aspects of 
inflammatory pain induced by CFA adjuvant. We also 
assessed hyperalgesia and edema during the long-term 
administration of MSC-CM. 
The results of this study indicated the role of 
MSC-CM in reducing edema and hyperalgesia during 
different stages of inflammation caused by CFA 
adjuvant. The continuing injection of MSC-CM could 
reduce the inflammatory symptoms to a time before 
induction of inflammation. Therefore, the CFA+CM 
group on day 21 of the study did not have significant 
difference with baseline and the control group.  
In this study plantar injection of CFA induced 
paw inflammation and edema which continued up to 
day 21 after the CFA injection. Hyperalgesia elevated 
considerably on day 7 after the CFA injection, but the 
continuity of inflammation declined hyperalgesia 
notably on days 14 and 21 of the study compared to 
day 7. Animal models of inflammatory and 
neuropathic pain are widely applied to study the 
mechanisms of acute and chronic pain (16). Arthritis 
model induced by CFA (containing inactivated 
Mycobacterium tuberculosis bacteria which is 
suspended in sterile mineral oil) in rats is an 
inflammatory model extensively used in 
etiopathogenic investigational drug and molecular 
studies due to its similarity to human RA and assay 
the pathophysiological and pharmacological changes 
during human RA (11).  
Intraplantar injection of inflammatory agents 
such as CFA causes elevated firing of peripheral 
afferents in the spinal cord, leading to hyperalgesia 
(17). Inflammatory pain is specified by an increased 
sensitivity to mechanical or thermal stimuli of the 
affected area. Subsequent of tissue injury, an 
inflammatory response is initiated by local 
macrophages and reinforced by migrating blood cells 
(1). Sensitization of the primary afferent nociceptive 
fiber during inflammation is an important factor in the 
 
Fig. 3.  Thermal hyperalgesia substantially incremented in different time points of the study in CFA group 
compared to day zero and long-term injection of MSC-CM considerably decremented thermal hyperalgesia. 
Results presented as Mean ± SEM (n= 6/group). 
 ** p≤0.01 and *** p≤0.001 for comparing the PWL alterations in CFA group between day 0 and different 
time points of the study. † p≤0.05 and †† p≤0.01 for comparing the PWL variations in CFA+CM group 
between day 0 and different time points of the study. ΔΔ p≤0.01 and ΔΔΔ p≤0.001for comparing the changes 
in PWL in the CFA+CM group at day 14 and day 21 compared to day 7. 
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creation and development of hyperalgesia (5, 6).  
The behavioral tests as an example 
hyperalgesia, following inflammatory pain conditions 
examine the changes in an animal’s responses to 
mechanical or heat stimuli and reflect an alteration of 
sensory processes. These behavioral tests have been 
effectual for elucidating the mechanisms of central 
and peripheral processes which occur in response to 
inflammation (16). 
Pursuant to Hargreaves study, rats due to its 
inflammation induced by plantar injection of CFA, 
had withdrawn his affected paw from the thermal 
stimuli, but some other studies have shown that motor 
behaviors subsequent of the inflammation are normal 
and no notable changes in motor activities are 
observed (18).  
A study illustrated that plantar injection of 
CFA incremented hyperalgesia and edema from 24 
hours after the CFA injection and continued up to the 
first week after the injection (14). However, Cicala et 
al, showed that hyperalgesia existed only between 
Days 14 and 21 subsequent of arthritis induction due 
to CFA injection (19). Other studies have indicated 
that hyperalgesia and edema induced by plantar 
injection of CFA two hours after the injection are 
initiated and continued for at least a month. The 
researchers expressed that injection of inflammatory 
factors such as CFA to the hind paw through lessen 
the stimulation threshold of peripheral afferents in the 
spinal cord lead to hyperalgesia and edema during the 
first weeks after intervention (6, 11, 20).  
Thermal hyperalgesia never happened in the 
contralateral paw during arthritis induced by CFA 
adjuvant. Injection of CFA into the one hind paw may 
have a pivotal role in the induction of hyperalgesia 
which occurs only in the ipsilateral paw, however the 
reasons for the absence of hyperalgesia in the 
contralateral paw should be clarified (6).  
The results of this study in line with previous 
studies have shown that inflammatory model induced 
by CA injection, is a biphasic model that in the first 
phase (acute phase) was associated with increase of 
pain and hyperalgesia due to the presence of pro-
inflammatory cytokines such as TNF-α and IL-1β 
while in the second phase (chronic phase), 
hyperalgesia substantially declined compared to the 
previous days due to the presence of opioid receptors 
(6). Hammond et al., represented that an increase in 
the potency of opioid agonists alleviates hyperalgesia 
as an example of inflammatory symptoms through 
inflammation and arthritis (21). Studies have 
suggested that MSC-CM containing multiple growth 
 
Fig. 4.  CFA injection considerably incremented thermal hyperalgesia while MSC-CM administration reduced 
thermal hyperalgesia compared to the CFA group substantially. Results stated as Mean±SEM (n=6/group). 
 * p≤0.05 and *** p≤0.001 for Comparing the PWL variations between CFA and CFA+CM groups in 
identical days. ϴϴϴ P≤0.001 for comparing the differences in PWL variations in CFA and CFA+CM groups 
at days 7 and 14 compared to day 21. 
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factors, anti-inflammatory mediators and different 
chemokines that can alleviate inflammatory 
symptoms and problems subsequently be involved.  
Scientists showed that MSC-CM not only 
through production of soluble trophic factors can 
stimulate intracellular mechanisms of damaged cells 
and inflammatory area but also by inducing secretion 
of functional active agents via neighboring cells can 
relieve symptoms of inflammation (8, 22, 23). 
accordingly, our results not only represent the 
effectual role of MSC-CM in the betterment of 
symptoms of acute phase of the inflammation induced 
by CFA, but also showed that continuing the 
administration of MSC-CM during inflammation 
could reduce inflammatory symptoms until day 21 of 
the study (chronic arthritic phase). 
Conclusion 
Our study showed that MSC-CM long term 
treatment significantly reduced hyperalgesia and paw 
edema during both acute and chronic phases of CFA-
induced inflammatory arthritis in male wistar rats. 
However, further studies are needed to evaluate the 
effect of MSC-CM on different aspects of 
inflammation, cytokines production and intracellular 
signaling pathways activity. 
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